Predictive PD-L1 immunohistochemistry for non-small cell lung cancer: Current state of the art and experiences of the first German harmonization study;Prädiktive PD-L1-Immunhistochemie beim nichtkleinzelligen Bronchialkarzinom: Aktueller Stand und Erfahrungen der ersten deutschen Harmonisierungsstudie

Pathologe

Volumn 37, Issue 6, 2016, Pages 557-567

  Scheel, A H ^a   Dietel, M ^b   Heukamp, L C ^c   Johrens K ^b   Kirchner, T ^d   Reu, S ^d   Ruschoff J ^e   Schildhaus, H U ^f   Schirmacher, P ^g   Tiemann, M ^c   Warth, A ^g   Weichert, W ^h   Fischer, R N ^a   Wolf, J ^a   Buttner R ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Institut für Hämatopathologie Hamburg   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e Institut fur Pathologie Nordhessen   (Germany)

^f UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^g UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Assessment algorithms; Harmonization; Immunotherapy; PD L1 IHC; Predictive biomarkers

Indexed keywords

CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; TUMOR MARKER;

ALGORITHM; CARCINOMA, NON-SMALL-CELL LUNG; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS;

ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LUNG NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 84981225204     PISSN: 01728113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00292-016-0189-1     Document Type: Article

References (36)

1. Gettinger SN, Horn L, Gandhi L et al (2015) Overall survival and long-term safety of Nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 33(18):2004–2012
2. Garon EB, Rizvi NA, Hui R (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372(21):2018–2028
3. Fehrenbacher L, Spira A, Ballinger M et al (2016) Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet:. doi:10.1016/s0140-6736(16)00587-0
4. Weber JS, D’Angelo SP, Minor D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16(4):375–384
5. Robert C, Schachter J, Long GV (2015) Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med 372(26):2521–2532
6. Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803–1813
7. Patnaik A, Kang SP, Rasco D et al (2015) Phase I study of Pembrolizumab (MK-3475; anti-PD-1 Monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res 21(19):4286–4293
8. Herbst RS, Soria JC, Kowanetz M et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528):563–567
9. Rosenberg JE, Hoffman-Censits J, Powles T et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet:. doi:10.1016/s0140-6736(16)00561-4
10. Westin JR, Chu F, Zhang M et al (2014) Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 1:69–77
11. Brahmer J, Reckamp KL, Baas P, Crinò L et al (2015) Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123–135
12. Borghaei H, Paz-Ares L, Horn L, Spigel DR et al (2015) Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627–1639
13. Herbst RS, Baas P, Kim DW et al (2015) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet:. doi:10.1016/s0140-6736(15)01281-7
14. Kerr KM, Tsao M‑S, Nicholson AG, Yatabe Y, Wistuba II, Hirsch FR (2015) PD-L1 immunohistochemistry in lung cancer: In what state is this art? J Thorac Oncol 10(7):985–989
15. Taube JM, Klein A, Brahmer JR et al (2014) Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20(19):5064–5074
16. Yearly JH, Gibson C, Yu N et al (2015) PD-L2 expression in human tumors: relevance to Anti-PD-1 Therapy in cancer. ECCO 2015.
17. Salgado R, Denkert C, Demaria S et al (2015) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26(2):259–271
18. Rizvi NA, Hellmann MD, Snyder A et al (2015) Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230):124–128
19. Van Allen EM, Miao D, Schilling B et al (2015) Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350(6257):207–211
20. FDA (2015) FDA news release 2015-09-10. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm466413.htm. Zugegriffen: 9. Febr. 2016
21. Wang C, Thudium KB, Han M et al (2014) In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res 2(9):846–856
22. Dako (2016) Produktinformationen Dako 28-8 pharmDx PD-L1 IHC Assay. http://www.dako.com/us/index/products/pd-l1-ihc-28-8.htm. Zugegriffen: 9. Febr. 2016
23. FDA (2015) FDA News Release 2015-04-10. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm. Zugegriffen: 9. Febr. 2016
24. Dako (2016) Produktinformationen Dako 22C3 pharmDx PD-L1 IHC Assay. http://www.dako.com/us/index/products/pd-l1-ihc-22C3.htm. Zugegriffen: 9. Febr. 2016
25. Gettinger SN, Kowanetz M, Koeppen et al (2015) Abstract #3015. Molecular, immune and histopathologic characterization of NSCLC based on PD-L1 expression on tumor and immune cells and association with response to the anti-PDL1 antibody atezolizumab. ASCO 2015.
26. Powles T, Eder JP, Fine GD et al (2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515(7528):558–562
27. Stewart R, Morrow M, Hammond SA et al (2015) Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol Res 3(9):1052–1062
28. Garon EB (2015) Current perspectives in immunotherapy for non-small cell lung cancer. Semin Oncol 42(Suppl 2):S11–S18
29. Boyerinas B, Jochems C, Fantini M et al (2015) Antibody-dependent cellular Cytotoxicity activity of a novel anti-PD-L1 antibody Avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res 3(10):1148–1157
30. Gulley JL, Spigel DR, Kelly K et al (2015) Abstract #8034. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: a phase Ib, open-label expansion trial in patients progressing after platinum-based chemotherapy. ASCO 2015.
31. FDA (2015) FDA News Release 2015-09-30. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm465274.htm. Zugegriffen: 9. Febr. 2016
32. Hirsch FR, Philip R, Averbuch SD et al (2016) The Blueprint Project: Harmonizing companion diagnostics across a class of targeted therapies. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16–20; New Orleans, LA. Philadelphia (PA)
33. European Medicines Agency (2015) Informationen zu „Opdivo“. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003985/human_med_001876.jsp. Zugegriffen: 27. Febr. 2016
34. European Medicines Agency (2015) Informationen zu „Keytruda. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003820/human_med_001886.jsp. Zugegriffen: 9. Febr. 2016
35. Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23–23
36. Scheel AH, Dietel M, Heukamp LC et al (2016) Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Modern Pathology advance online publication 8 July 2016; doi: 10.1038/modpathol.2016.117